沙利度胺联合华蟾素治疗肺癌恶病质的临床研究
Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia.
作者信息
Xie Mingzhi, Chen Xiaoju, Qin Shouming, Bao Yongjian, Bu Kunpeng, Lu Yang
机构信息
Department of Medical Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Department of Respiration, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
出版信息
J Cancer Res Ther. 2018 Jan;14(1):226-232. doi: 10.4103/0973-1482.188436.
OBJECTIVE
To discuss and assess the clinical value of treating lung cancer cachexia with thalidomide combined with cinobufagin.s.
METHODS
A cohort of 54 patients, who were diagnosed with lung carcinoma, was randomly divided into two groups, a trial group and a control group, respectively. The trial group was given 150 mg/day thalidomide and 2700 mg/day cinobufagin; the control group only received 2,700 mg/day cinobufagin. The therapy lasted for 12 weeks, and the nutritional status, quality of life, survival, and side effects in patients in the two groups were recorded.
RESULTS
The nutritional status, quality of life, and survival of patients with lung cancer cachexia in the trial group were significantly improved compared to the control group. The trial group received 150 mg thalidomide, which by contrast reduced the incidence of side effect and increased tolerance.
CONCLUSION
Using thalidomide combined with cinobufagin to treat patients with lung cancer cachexia will significantly improve their nutritional status and quality of life. This therapy is better than that using cinobufagin alone and is well tolerated.
目的
探讨并评估沙利度胺联合华蟾素治疗肺癌恶病质的临床价值。
方法
将54例确诊为肺癌的患者随机分为两组，即试验组和对照组。试验组给予沙利度胺150mg/天和华蟾素2700mg/天；对照组仅接受华蟾素2700mg/天。治疗持续12周，记录两组患者的营养状况、生活质量、生存期及副作用。
结果
与对照组相比，试验组肺癌恶病质患者的营养状况、生活质量及生存期均有显著改善。试验组服用150mg沙利度胺，相比之下降低了副作用发生率并提高了耐受性。
结论
使用沙利度胺联合华蟾素治疗肺癌恶病质患者可显著改善其营养状况和生活质量。该疗法优于单独使用华蟾素，且耐受性良好。
Zotero 插件